OAM
CAPR icon

Oxford Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Oxford Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,784
Closed -$45K – 1629
2017
Q4 		$45K Buy
+2,784
New +$60.3K ﹤0.01% 1567

Other funds holding CAPR

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
AA
Apriem Advisors Irvine, California $1.05B AUM 22.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Oxford Asset Management's CAPR Position: Q1 2018 in Review

Oxford Asset Management sold out of Capricor Therapeutics (CAPR) in Q1 2018, closing a stake of 2,784 shares — an estimated $45K sold.

Oxford Asset Management first reported a position in CAPR in Q4 2017 and held it in 1 quarter. The position peaked at $45K in Q4 2017. 20 funds tracked by Wall St. Rank hold CAPR as of Q1 2018.

  • Oxford Asset Management reported no remaining Capricor Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Oxford Asset Management sold 2,784 Capricor Therapeutics shares in Q1 2018, an estimated $45K.
  • Oxford Asset Management first reported a position in Capricor Therapeutics in Q4 2017 and held it in 1 quarter.
  • Oxford Asset Management's Capricor Therapeutics position peaked at $45K in Q4 2017.
  • 20 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2018.

Based on Oxford Asset Management's 13F filing for Q1 2018, filed 15 May 2018.